Monday's top analyst upgrades and downgrades included Akamai Technology, ContextLogic, DuPont de Nemours, First Solar, Peabody Energy, Southwest Airlines, 3M and Union Pacific.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Delta Airlines, Foot Locker, Nvidia and Petrobras.
Monday's top analyst upgrades and downgrades included American Eagle Outfitters, Baidu, GameStop, Halliburton, Mosaic, Regeneron Pharmaceuticals, Salesforce.com, Take-Two Interactive Software and Wells Fargo.
Tuesday's top analyst upgrades and downgrades include Apple, Baidu, Boeing, Delta Air Lines, L3Harris Technologies, Moderna, Raytheon Technologies, Roku and Walt Disney.
Thursday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, Applied Materials, Carnival, Dell, Karuna Therapeutics, Lowe's, Noble Energy, PayPal, Square, Target and Virgin Galactic.
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.
The top analyst upgrades, downgrades and other research calls from Monday included Akamai, Dollar Tree, Hasbro, Intel, Mylan, Netflix and Papa John's.
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
The top analyst upgrades, downgrades and other research calls from Wednesday include Accenture, American Expresss, Cognizant Technology Solutions, FireEye, Mastercard, PayPal, Verizon and Visa.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
